TABLE 3.
Lymphocytes and T cell counts at COVID-19 diagnosis and during follow-up
| Patienta | Lymphocyte counts at diagnosis (N: 1200-4000/mm3) | Day of ELISPOT testing post–symptom onsetb | Lymphocytes counts at ELISPOT testing (/mm3) (N: 1200-4000/mm3) | Total T cells at ELISPOT testing |
SARS-CoV–2- reactive T cellsc |
||||
|---|---|---|---|---|---|---|---|---|---|
| %CD3 (N: 56%–84%) | CD3 (N: 1400 –3300/mm3) | CD4 (N: 1000 - 2200/mm3) | CD8 (N: 330 - 920/mm3) | /mm3 | % or ‰ of CD3+ T cells | ||||
| Kidney transplanted patients | |||||||||
| KTX1 | 380 | 19 60 |
960 1743 |
76.7% 86.7% |
736 1512 |
304 577 |
426 1002 |
2.5 3.9 |
0.33% 0.26% |
| KTX2 | 730 | 31 53 |
3672 2977 |
84.8% 84.6% |
3114 2519 |
2014 1595 |
1041 897 |
21.1 7.4 |
0.68% 0.29% |
| KTX3 | 530 | 26 | 601 | 80.2% | 482 | 266 | 203 | 5.9 | 0.25% |
| KTX4 | 1010 | 42 | 1681 | 80.6% | 1355 | 848 | 452 | 1.5 | 0.11% |
| KTX5 | 190 | 39 56 |
549 725 |
79.2% 81.0% |
435 587 |
156 221 |
267 326 |
0.4 0.3 |
0.08% 0.07% |
| KTX6 | 1080 | 50 | 1099 | 61.7% | 678 | 412 | 258 | 0.0 | 0.0% |
| KTX7 | 1300 | 48 | 1297 | 74.3% | 964 | 481 | 358 | 0.07 | 0.08‰ |
| KTX8 | 1310 | 37 | 780 | 91.0% | 710 | 231 | 449 | 0.00 | 0.0% |
| KTX9 | 590 | 37 | 1344 | 66.1% | 888 | 618 | 249 | 0.02 | 0.02‰ |
| KTX10 | 2230 | 40 | 1789 | 67.4% | 1206 | 836 | 353 | 0.03 | 0.03‰ |
| KTX11 | 1040 | 49 | 1488 | 84.9% | 1263 | 499 | 715 | 0.00 | 0.0% |
| Patients on hemodialysis | |||||||||
| HD1 | 260 | 21 | 955 | 71.5% | 683 | 347 | 331 | 3.1 | 0.45% |
| HD2 | 570 | 17 | 777 | 69.6% | 541 | 358 | 167 | 4.5 | 0.83% |
Abbreviation: N, normal values.
a
Patients with confirmed COVID-19 (RT-PCR positive) are highlighted in bold.
b
Two values are shown for patients KTX1, KTX2, and KTX5 who were tested twice.
c
The frequency of SARS-CoV-2–reactive T cells, as detected by ELISPOT assay, is expressed either as counts per mm3 of peripheral blood or as proportions (% or ‰) of total CD3+ T cells.